Substance Use Disorder and COVID-19; Forensic Medicine and Pharmacology Perspectives: A Concise Narrative Review

Ahmed Ali; Torki  Al-Zughaibi; Assmaa  A. Shaker

doi:10.26735/JABO2616

Pdf

Published 28-12-2021

DOI https://doi.org/10.26735/JABO2616

How to Cite

1.

Substance Use Disorder and COVID-19; Forensic Medicine and Pharmacology Perspectives: A Concise Narrative Review. AJFSFM [Internet]. 2021 Dec. 28 [cited 2026 Nov. 6];3(2):315-30. Available from: https://journals.nauss.edu.sa/AJFSFM/article/view/1551

Download Citation

Ahmed S. Ali

Department of Pharmacology, College of Medicine, King Abdelaziz University, Saudi Arabia.

Torki Al-Zughaibi

Department of Medical Laboratory Technologies, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.

Assmaa A. Shaker

Medical Student, Ibn Sina National College of Medicine, Jeddah, Saudi Arabia

Abstract

Many investigations have confirmed the link between a substance use disorder (SUD) and the COVID-19 pandemic's increased risk of infection and consequences. This narrative review aims to understand these issues from a pharmacological standpoint, as well as the pandemic's impact on forensic medicine.
Research and review articles included in this review were selected through an extensive search of databases such as PubMed and the use of appropriate keywords e.g. “substance use disorder” and “COVID-19”. Due to a weakened immune system and degeneration of the respiratory system's defense systems, SUDs have been shown to increase the risk of COVID-19 infection. Furthermore, some substances raise pro-inflammatory mediators, exposing the body to a cytokine storm. SUD frequently causes secondary comorbidities, such as the liver, lung and cardiovascular disease, complicating the treatment of COVID-19 infections. Some misused substances can compromise the treatment's effectiveness or safety.
This study also looked at the effects of the pandemic on forensic medicine. It underlines the importance of developing safe forensic examination procedures and methodologies during pandemics. The use of narcotic substances was documented as one of the reasons for the increase in the frequency of COVID-19 and the severity of its repercussions.

Keywords

Forensic Science, COVID 19, SARS-COV-2, Alcoholism, Substance Use Disorder, Opioids, Nicotine, Cannabinoids, Cocaine, Methamphetamine

Downloads

Download data is not yet available.

References

Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus pandemic (COVID-19). Our world in data. 2020 May 26.

Singh SP, Pritam M, Pandey B, Yadav TP. Microstructure, pathophysiology, and potential therapeutics of COVID‐19: a comprehensive review. Journal of medical virology. 2021 Jan;93(1):275-99. https://doi.org/10.1002/jmv.26254.

Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, Scarlata S, Agrò FE. COVID‐19 diagnosis and management: a comprehensive review. Journal of internal medicine. 2020 Aug;288(2):192-206. https://doi.org/10.1111/joim.13091.

Kang Y, Xu S. Comprehensive overview of COVID‐19 based on current evidence. Dermatologic therapy. 2020 Sep;33(5):e13525. https://doi.org/10.1111/dth.13525.

Diagnostic AP. statistical manual of mental disorders: DSM-5™. Arlington. VA American Psychiatric Publishing. 2013.

APA. Help With Addiction and Substance Use Disorders. 2021 [cited 2021 12 June]; Available from: https://www.psychiatry.org/patients-families/addiction.

UNODC. World Drug Report 2019. United Nations Office on Drugs and Crime (UNODC). 2019 [cited 2021 10 June]; Available from: https://wdr.unodc.org/wdr2019/.

World Health Organization. Global status report on alcohol and health 2018. World Health Organization; 2019 Feb 14.

Schulte MT, Hser YI. Substance use and associated health conditions throughout the lifespan. Public health reviews. 2013 Dec 1;35(2):3. https://doi.org/10.1007/BF03391702.

Dubey MJ, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S. COVID-19 and addiction. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020 Sep 1;14(5):817-23. https://doi.org/10.1016/j.dsx.2020.06.008.

Ornell F, Moura HF, Scherer JN, Pechansky F, Kessler FH, von Diemen L. The COVID-19 pandemic and its impact on substance use: implications for prevention and treatment. Psychiatry research. 2020 Jul 1;289:113096. https://doi.org/10.1016/j.psychres.2020.113096.

Zaami S, Marinelli E, Varì MR. New trends of substance abuse during COVID-19 pandemic: an international perspective. Frontiers in Psychiatry. 2020 Jul 16;11:700. https://doi.org/10.3389/fpsyt.2020.00700.

Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A national qualitative assessment in Canada. International Journal of Drug Policy. 2021 Jul 1;93:103237. https://doi.org/10.1016/j.drugpo.2021.103237.

Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19.

Althobaiti YS, Alzahrani MA, Alsharif NA, Alrobaie NS, Alsaab HO, Uddin MN. The Possible Relationship between the Abuse of Tobacco, Opioid, or Alcohol with COVID-19. InHealthcare 2021 Jan (Vol. 9, No. 1, p. 2). Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/healthcare9010002.

Ataei M, Shirazi FM, Lamarine RJ, Nakhaee S, Mehrpour O. A double-edged sword of using opioids and COVID-19: a toxicological view. Substance Abuse Treatment, Prevention, and Policy. 2020 Dec;15(1):1-4. https://doi.org/10.1186/s13011-020-00333-y.

Ayad AE. Opioid epidemics during the pandemic: Further insights to the same story. Journal of Opioid Management. 2021 Jan 1;17(1):9-12. https://doi.org/10.5055/jom.2021.0609.

Marel C, Mills KL, Teesson M. Substance use, mental disorders and COVID-19: a volatile mix. Current Opinion in Psychiatry. 2021 Jul;34(4):351. https://doi.org/10.1097/YCO.0000000000000707.

United-Nations. WDR21_Booklet_5.pdf. 2021 June 2021 [cited 2021 17 october]; Available from: https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_5.pdf.

Farhoudian A, Baldacchino A, Clark N, Gerra G, Ekhtiari H, Dom G, Mokri A, Sadeghi M, Nematollahi P, Demasi M, Schütz CG. COVID-19 and substance use disorders: recommendations to a comprehensive healthcare response. An international society of addiction medicine practice and policy interest group position paper. Basic and Clinical Neuroscience. 2020 Mar;11(2):133. https://doi.org/10.32598/bcn.11.covid19.1.

Bogdanović M, Atanasijević T, Popović V, Mihailović Z, Radnić B, Durmić T. Is the role of forensic medicine in the covid-19 pandemic underestimated?. Forensic Science, Medicine and Pathology. 2021 Mar;17(1):136-8. https://doi.org/10.1007/s12024-020-00308-2.

Mawalla WF. The contribution of autopsy in COVID-19 pandemic: Missed opportunity in Sub-Saharan Africa. Forensic Science International: Reports. 2020 Dec 1;2:100136. https://doi.org/10.1016/j.fsir.2020.100136.

O'Neal CL, Poklis A. Postmortem production of ethanol and factors that influence interpretation: a critical review. The American journal of forensic medicine and pathology. 1996 Mar 1;17(1):8-20. https://doi.org/10.1097/00000433-199603000-00002.

Salerno M, Sessa F, Piscopo A, Montana A, Torrisi M, Patanè F, Murabito P, Li Volti G, Pomara C. No autopsies on COVID-19 deaths: a missed opportunity and the lockdown of science. Journal of clinical medicine. 2020 May;9(5):1472. https://doi.org/10.3390/jcm9051472.

Tozzo P, D’Angiolella G, Caenazzo L. Prisoners in a pandemic: We should think about detainees during Covid-19 outbreak. Forensic Science International: Synergy. 2020 Jan 1;2:162-3. https://doi.org/10.1016/j.fsisyn.2020.05.004.

Yang H, Thompson JR. Fighting covid-19 outbreaks in prisons. BMJ. 2020 Apr 2;369. https://doi.org/10.1136/bmj.m1362.

Wei Y, Shah R. Substance use disorder in the COVID-19 pandemic: a systematic review of vulnerabilities and complications. Pharmaceuticals. 2020 Jul;13(7):155. https://doi.org/10.3390/ph13070155.

Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Molecular psychiatry. 2021 Jan;26(1):30-9. https://doi.org/10.1038/s41380-020-00880-7.

Baillargeon J, Polychronopoulou E, Kuo YF, Raji MA. The impact of substance use disorder on COVID-19 outcomes. Psychiatric Services. 2021 May;72(5):578-81. https://doi.org/10.1176/appi.ps.202000534.

Allen B, El Shahawy O, Rogers ES, Hochman S, Khan MR, Krawczyk N. Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January–October 2020. Journal of Public Health. 2021 Sep;43(3):462-5. https://doi.org/10.1093/pubmed/fdaa241.

Vallecillo G, Perelló R, Güerri R, Fonseca F, Torrens M. Clinical impact of COVID-19 on people with substance use disorders. Journal of Public Health. 2021 Mar;43(1):9-12. https://doi.org/10.1093/pubmed/fdaa181.

Sajja RK, Rahman S, Cucullo L. Drugs of abuse and blood-brain barrier endothelial dysfunction: A focus on the role of oxidative stress. Journal of Cerebral Blood Flow & Metabolism. 2016 Mar;36(3):539-54. https://doi.org/10.1177/0271678X15616978.

Armario A. Activation of the hypothalamic–pituitary–adrenal axis by addictive drugs: different pathways, common outcome. Trends in Pharmacological Sciences. 2010 Jul 1;31(7):318-25. https://doi.org/10.1016/j.tips.2010.04.005.

Shield K, Manthey J, Rylett M, Probst C, Wettlaufer A, Parry CD, Rehm J. National, regional, and global burdens of disease from 2000 to 2016 attributable to alcohol use: a comparative risk assessment study. The Lancet Public Health. 2020 Jan 1;5(1):e51-61. https://doi.org/10.1016/S2468-2667(19)30231-2.

Stockwell T, Andreasson S, Cherpitel C, Chikritzhs T, Dangardt F, Holder H, Naimi T, Sherk A. The burden of alcohol on health care during COVID‐19. Drug and Alcohol Review. 2021 Jan;40(1):3-7. https://doi.org/10.1111/dar.13143.

Farmer B. Toxic alcohol kills more than 700 in Iran following false reports it wards off coronavirus. The Telegraph.–2020.–URL: https://www. telegraph. co. uk/global-health/science-anddisease/toxic-alcohol-kills-700-iran-following-false-reports-ward-coronavirus. 2020.

Neufeld M, Lachenmeier DW, Ferreira‐Borges C, Rehm J. Is Alcohol an “Essential Good” During COVID‐19? Yes, but Only as a Disinfectant!. Alcoholism: Clinical and Experimental Research. 2020 Sep;44(9):1906-9. https://doi.org/10.1111/acer.14417.

Pasala S, Barr T, Messaoudi I. Impact of alcohol abuse on the adaptive immune system. Alcohol research: current reviews. 2015;37(2):185.

Simou E, Britton J, Leonardi-Bee J. Alcohol and the risk of pneumonia: a systematic review and meta-analysis. BMJ open. 2018 Aug 1;8(8):e022344. https://doi.org/10.1136/bmjopen-2018-022344.

Bartoletti M, Giannella M, Lewis RE, Viale P. Bloodstream infections in patients with liver cirrhosis. Virulence. 2016 Apr 2;7(3):309-19. https://doi.org/10.1080/21505594.2016.1141162.

Okuno F, Arai M, Ishii H, Shigeta Y, Ebihara Y, Takagi S, Tsuchiya M. Mild but prolonged elevation of serum angiotensin converting enzyme (ACE) activity in alcoholics. Alcohol. 1986 Nov 1;3(6):357-9. https://doi.org/10.1016/0741-8329(86)90053-4.

Testino G. Are patients with alcohol use disorders at increased risk for Covid-19 infection?. Alcohol and Alcoholism. 2020 Jun 25;55(4):344-6. https://doi.org/10.1093/alcalc/agaa037.

Ojo AS, Akin-Onitolo A, Okediji P, Balogun S. COVID-19 and Alcoholism: A Dangerous Synergy?. Journal of Contemporary Studies in Epidemiology and Public Health. 2020 Jul 30;1(1):ep20002. https://doi.org/10.30935/jconseph/8441.

Da BL, Im GY, Schiano TD. Coronavirus disease 2019 hangover: a rising tide of alcohol use disorder and alcohol‐associated liver disease. Hepatology. 2020 Sep;72(3):1102-8. https://doi.org/10.1002/hep.31307.

Clay JM, Parker MO. Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis?. The Lancet. Public Health. 2020 May;5(5):e259. https://doi.org/10.1016/S2468-2667(20)30088-8.

Eric and Strain. Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis. 2021 [cited 2021 17 Octiober]; Available from: https://www.uptodate.com/contents/opioid-use-disorder-epidemiology-pharmacology-clinical-manifestations-course-screening-assessment-and-diagnosis.

James A, Williams J. Basic opioid pharmacology—an update. British Journal of Pain. 2020 May;14(2):115-21. https://doi.org/10.1177/2049463720911986.

Schimmel J, Manini AF. Opioid use disorder and COVID-19: biological plausibility for worsened outcomes. Substance use & misuse. 2020 Aug 3;55(11):1900-1. https://doi.org/10.1080/10826084.2020.1791184.

Lambert DG. Opioids and the COVID-19 pandemic: does chronic opioid use or misuse increase clinical vulnerability?. BJA: British Journal of Anaesthesia. 2020 Oct;125(4):e382. https://doi.org/10.1016/j.bja.2020.07.004.

Kiyatkin EA. Respiratory depression and brain hypoxia induced by opioid drugs: Morphine, oxycodone, heroin, and fentanyl. Neuropharmacology. 2019 Jun 1;151:219-26. https://doi.org/10.1016/j.neuropharm.2019.02.008.

Hudzik B, Nowak J, Zubelewicz-Szkodzinska B. Consideration of immunomodulatory actions of morphine in COVID-19-Short report. Eur Rev Med Pharmacol Sci. 2020 Dec 1;24(24):13062-4.

Schimmel J, Manini AF. Opioid use disorder and COVID-19: biological plausibility for worsened outcomes. Substance use & misuse. 2020 Aug 3;55(11):1900-1. https://doi.org/10.1080/10826084.2020.1791184.

Mitchell M, Shee K, Champlin K, Essary AC, Evans M. Opioid use disorder and COVID-19: Implications for policy and practice. Journal of the American Academy of PAs. 2021 Jun 1;34(6):1-4. https://doi.org/10.1097/01.JAA.0000742976.14811.36.

Gisev N, Bharat C, Larney S, Dobbins T, Weatherburn D, Hickman M, Farrell M, Degenhardt L. The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. The Lancet Public Health. 2019 Jul 1;4(7):e334-42. https://doi.org/10.1016/S2468-2667(19)30060-X.

Elliott L, Benoit E, Matusow H, Rosenblum A. Disaster preparedness among opioid treatment programs: Policy recommendations from state opioid treatment authorities. International journal of disaster risk reduction. 2017 Aug 1;23:152-9. https://doi.org/10.1016/j.ijdrr.2017.05.001.

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. bmj. 2017 Apr 26;357. https://doi.org/10.1136/bmj.j1550.

Sun Y, Bao Y, Kosten T, Strang J, Shi J, Lu L. Challenges to opioid use disorders during COVID‐19. The American journal on addictions. 2020 May;29(3):174. https://doi.org/10.1111/ajad.13031.

Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present–a pharmacological and clinical perspective. Journal of psychopharmacology. 2013 Jun;27(6):479-96. https://doi.org/10.1177/0269881113482532.

Vearrier D, Greenberg MI, Miller SN, Okaneku JT, Haggerty DA. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Disease-a-Month. 2012 Feb 1;58(2):38-89. https://doi.org/10.1016/j.disamonth.2011.09.004.

Hellem TL. A review of methamphetamine dependence and withdrawal treatment: a focus on anxiety outcomes. Journal of substance abuse treatment. 2016 Dec 1;71:16-22. https://doi.org/10.1016/j.jsat.2016.08.011.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020 Apr 7;323(13):1239-42. https://doi.org/10.1001/jama.2020.2648.

Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF, Chernyak Y, Tobin K, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. MedRxiv. 2020 Jan 1. https://doi.org/10.1101/2020.04.08.20057794.

Zhao SX, Kwong C, Swaminathan A, Gohil A, Crawford MH. Clinical characteristics and outcome of methamphetamine-associated pulmonary arterial hypertension and dilated cardiomyopathy. JACC: Heart Failure. 2018 Mar;6(3):209-18. https://doi.org/10.1016/j.jchf.2017.10.006.

Won S, Hong RA, Shohet RV, Seto TB, Parikh NI. Methamphetamine‐associated cardiomyopathy. Clinical cardiology. 2013 Dec;36(12):737-42. https://doi.org/10.1002/clc.22195.

Hossain MK, Hassanzadeganroudsari M, Apostolopoulos V. Why METH users are at high risk of fatality due to COVID-19 infection?. https://doi.org/10.1080/14760584.2020.1858059.

Prakash MD, Tangalakis K, Antonipillai J, Stojanovska L, Nurgali K, Apostolopoulos V. Methamphetamine: effects on the brain, gut and immune system. Pharmacological research. 2017 Jun 1;120:60-7. https://doi.org/10.1016/j.phrs.2017.03.009.

Salamanca SA, Sorrentino EE, Nosanchuk JD, Martinez LR. Impact of methamphetamine on infection and immunity. Frontiers in neuroscience. 2015 Jan 12;8:445. https://doi.org/10.3389/fnins.2014.00445.

Harms R, Morsey B, Boyer CW, Fox HS, Sarvetnick N. Methamphetamine administration targets multiple immune subsets and induces phenotypic alterations suggestive of immunosuppression. PloS one. 2012 Dec 5;7(12):e49897. https://doi.org/10.1371/journal.pone.0049897.

Burns A, Ciborowski P. Acute exposure to methamphetamine alters TLR9-mediated cytokine expression in human macrophage. Immunobiology. 2016 Feb 1;221(2):199-207. https://doi.org/10.1016/j.imbio.2015.09.006.

Havakuk O, Rezkalla SH, Kloner RA. The cardiovascular effects of cocaine. Journal of the American College of Cardiology. 2017 Jul 4;70(1):101-13. https://doi.org/10.1016/j.jacc.2017.05.014.

Bachi K, Mani V, Jeyachandran D, Fayad ZA, Goldstein RZ, Alia-Klein N. Vascular disease in cocaine addiction. Atherosclerosis. 2017 Jul 1;262:154-62. https://doi.org/10.1016/j.atherosclerosis.2017.03.019.

Mégarbane B, Chevillard L. The large spectrum of pulmonary complications following illicit drug use: features and mechanisms. Chemico-biological interactions. 2013 Dec 5;206(3):444-51. https://doi.org/10.1016/j.cbi.2013.10.011.

National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research.

Maggirwar SB, Khalsa JH. The Link between Cannabis Use, Immune System, and Viral Infections. Viruses. 2021 Jun;13(6):1099. https://doi.org/10.3390/v13061099.

Farhoudian A, Radfar SR, Mohaddes Ardabili H, Rafei P, Ebrahimi M, Khojasteh Zonoozi A, De Jong CA, Vahidi M, Yunesian M, Kouimtsidis C, Arunogiri S. A global survey on changes in the supply, price, and use of illicit drugs and alcohol, and related complications during the 2020 COVID-19 pandemic. Frontiers in psychiatry. 2021:1134. https://doi.org/10.3389/fpsyt.2021.646206.

Van Laar MW, Oomen PE, Van Miltenburg CJ, Vercoulen E, Freeman TP, Hall WD. Cannabis and COVID-19: reasons for concern. Frontiers in Psychiatry. 2020 Dec 21;11:1419. https://doi.org/10.3389/fpsyt.2020.601653.

Hindocha C, Freeman TP, Ferris JA, Lynskey MT, Winstock AR. No smoke without tobacco: a global overview of cannabis and tobacco routes of administration and their association with intention to quit. Frontiers in psychiatry. 2016 Jul 5;7:104. https://doi.org/10.3389/fpsyt.2016.00104.

Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD, van Der Voort PH. Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). The Journal of pathology. 2020 Jul;251(3):228-48. https://doi.org/10.1002/path.5471.

Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tobacco induced diseases. 2020;18. https://doi.org/10.18332/tid/119324.

Paland N, Pechkovsky A, Aswad M, Hamza H, Popov T, Shahar E, Louria-Hayon I. The Immunopathology of COVID-19 and the Cannabis Paradigm. Frontiers in Immunology. 2021 Feb 12;12:327. https://doi.org/10.3389/fimmu.2021.631233.

Khalsa JH, Bunt G, Maggirwar SB, Kottilil S. COVID-19 and cannabidiol (CBD). Journal of Addiction Medicine. 2021 Sep;15(5):355. https://doi.org/10.1097/ADM.0000000000000771.

Borgonhi EM, Volpatto VL, Ornell F, Rabelo-da-Ponte FD, Kessler FH. Multiple clinical risks for cannabis users during the COVID-19 pandemic. Addiction Science & Clinical Practice. 2021 Dec;16(1):1-4. https://doi.org/10.1186/s13722-021-00214-0.

Jayes L, Haslam PL, Gratziou CG, Powell P, Britton J, Vardavas C, Jimenez-Ruiz C, Leonardi-Bee J, Dautzenberg B, Lundbäck B, Fletcher M. SmokeHaz: systematic reviews and meta-analyses of the effects of smoking on respiratory health. Chest. 2016 Jul 1;150(1):164-79. https://doi.org/10.1016/j.chest.2016.03.060.

Waziry R, Jawad M, Ballout RA, Al Akel M, Akl EA. The effects of waterpipe tobacco smoking on health outcomes: an updated systematic review and meta-analysis. International journal of epidemiology. 2017 Feb 1;46(1):32-43. https://doi.org/10.1093/ije/dyw021.

Jiménez-Ruiz CA, López-Padilla D, Alonso-Arroyo A, Aleixandre-Benavent R, Solano-Reina S, de Granda-Orive JI. COVID-19 and Smoking: A Systematic Review and Meta-Analysis of the Evidence. Archivos de bronconeumologia. 2020 Jul 25;57:21-34. https://doi.org/10.1016/j.arbres.2020.06.024.

Kang S, Gong X, Yuan Y. Association of smoking and cardiovascular disease with disease progression in COVID-19: A systematic review and meta-analysis. Epidemiology & Infection. 2021 May 12:1-26. https://doi.org/10.1017/S0950268821001138.

Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine and Tobacco Research. 2020 Sep;22(9):1653-6. https://doi.org/10.1093/ntr/ntaa082.

Patanavanich R, Glantz SA. Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: A systematic review and meta-analysis. BMC Public Health. 2021 Dec;21(1):1-9. https://doi.org/10.1186/s12889-021-11579-x.

Skalny AV, Lima TR, Ke T, Zhou JC, Bornhorst J, Alekseenko SI, Aaseth J, Anesti O, Sarigiannis DA, Tsatsakis A, Aschner M. Toxic metal exposure as a possible risk factor for COVID-19 and other respiratory infectious diseases. Food and Chemical Toxicology. 2020 Dec 1;146:111809. https://doi.org/10.1016/j.fct.2020.111809.

Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tobacco induced diseases. 2020;18. https://doi.org/10.18332/tid/119324.

Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, You R, Hong MJ, Baghaei N, Song LZ, Porter P, Putluri N. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. The Journal of clinical investigation. 2020 Apr 7;129(10):4290-304. https://doi.org/10.1172/JCI128531.

Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine and Tobacco Research. 2020 Sep;22(9):1653-6. https://doi.org/10.1093/ntr/ntaa082.

Jiménez-Ruiz CA, López-Padilla D, Alonso-Arroyo A, Aleixandre-Benavent R, Solano-Reina S, de Granda-Orive JI. COVID-19 and Smoking: A Systematic Review and Meta-Analysis of the Evidence. Archivos de bronconeumologia. 2020 Jul 25;57:21-34. https://doi.org/10.1016/j.arbres.2020.06.024.

Umnuaypornlert A, Kanchanasurakit S, Lucero-Prisno DE, Saokaew S. Smoking and risk of negative outcomes among COVID-19 patients: A systematic review and meta-analysis. Tobacco induced diseases. 2021;19. https://doi.org/10.18332/tid/132411.

Geng Y, Savage SM, Razani-Boroujerdi S, Sopori ML. Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy. The Journal of Immunology. 1996 Apr 1;156(7):2384-90.

Zhou Z, Chen P, Peng H. Are healthy smokers really healthy?. Tobacco induced diseases. 2016 Dec;14(1):1-2. https://doi.org/10.1186/s12971-016-0101-z.

Mazzone P, Tierney W, Hossain M, Puvenna V, Janigro D, Cucullo L. Pathophysiological impact of cigarette smoke exposure on the cerebrovascular system with a focus on the blood-brain barrier: expanding the awareness of smoking toxicity in an underappreciated area. International journal of environmental research and public health. 2010 Dec;7(12):4111-26. https://doi.org/10.3390/ijerph7124111.

Hutamekalin P, Farkas AE, Orbók A, Wilhelm I, Nagyőszi P, Veszelka S, Deli MA, Buzás K, Hunyadi‐Gulyás É, Medzihradszky KF, Meksuriyen D. Effect of nicotine and polyaromtic hydrocarbons on cerebral endothelial cells. Cell biology international. 2008 Feb;32(2):198-209. https://doi.org/10.1016/j.cellbi.2007.08.026.

Bradford ST, Stamatovic SM, Dondeti RS, Keep RF, Andjelkovic AV. Nicotine aggravates the brain postischemic inflammatory response. American Journal of Physiology-Heart and Circulatory Physiology. 2011 Apr;300(4):H1518-29. https://doi.org/10.1152/ajpheart.00928.2010.

Cattaruzza MS, Zagà V, Gallus S, D’Argenio P, Gorini G. Tobacco smoking and COVID-19 pandemic: old and new issues. A summary of the evidence from the scientific literature. Acta Bio Medica: Atenei Parmensis. 2020;91(2):106.

Olds JL, Kabbani N. Is nicotine exposure linked to cardiopulmonary vulnerability to COVID‐19 in the general population?. The FEBS journal. 2020 Sep;287(17):3651-5. https://doi.org/10.1111/febs.15303.

Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, Dorscheid DR, Sin DD. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. European Respiratory Journal. 2020 May 1;55(5). https://doi.org/10.1183/13993003.00688-2020.

Issue

Vol. 3 No. 2 (2021)

Section

Review Article

Copyright Information